Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab

Clinical Colorectal Cancer

Volumn 12, Issue 1, 2013, Pages 45-53

  Ricotta, Riccardo ^a   Vanzulli, Angelo ^a   Moroni, Mauro ^a   Colnago, Barbara ^a   Oriani, Matteo ^a   Nichelatti, Michele ^a   Sarnataro, Carolina ^a   Venturini, Filippo ^a   Di Bella, Sara ^a   Maiolani, Martina ^a   Giganti, Maria Olga ^a   Sartore Bianchi, Andrea ^a   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cetuximab; Magnetic resonance imaging; Metastatic colorectal cancer; Panitumumab; Predictor clinical outcome

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; LENALIDOMIDE; PANITUMUMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL ARTICLE; COLON METASTASIS; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY;

EID: 84874691266     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.07.001     Document Type: Article

References (38)

1. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
2. A. Bardelli, S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
3. N. Mittmann, H.J. Au, D. Tu Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial J Natl Cancer Inst 101 2009 1182 1192
4. N. Starling, D. Tilden, J. White Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment Br J Cancer 96 2007 206 212
5. W. De Roock, H. Piessevaux, J. De Schutter KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 2008 508 515
6. H. Piessevaux, M. Buyse, W. De Roock Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) Ann Oncol 20 2009 1375 1382
7. J. Ward, J.A. Guthrie, D. Wilson Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging: comparison of optimized sequences Radiology 228 2003 709 718
8. H. Kondo, M. Kanematsu, H. Hoshi Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT AJR Am J Roentgenol 174 2000 947 954
9. A phase 2, open-label study to evaluate the efficacy and safety of lenalidomide in combination with cetuximab in pretreated subjects with K-Ras mutant metastatic colorectal cancer NCT01032291. Clinicaltrials.gov [Web site] http://www.clinicaltrials.gov/ct2/show/NCT01032291?term=lenalidomide&recr= Closed&cntry1=EU%3AIT&rank=1 Accessed: September 15, 2011
10. A. Trotti, A.D. Colevas, A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment [review] Semin Radiat Oncol 13 2003 176 181
11. E.A. Eisenhauer, P. Therasse, J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
12. I.M. Desar, C.M. van Herpen, H.W. van Laarhoven Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy Cancer Treat Rev 35 2009 309 321
13. C.C. Jaffe Measures of response: RECIST, WHO, and new alternatives J Clin Oncol 24 2006 3245 3251
14. T.G. Karrison, M.L. Maitland, W.M. Stadler Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer J Natl Cancer Inst 99 2007 1455 1461
15. C.J. Bruns, M.T. Harbison, D.W. Davis Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms Clin Cancer Res 6 2000 1936 1948
16. P. Perrotte, T. Matsumoto, K. Inoue Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 1999 257 265
17. C. Bangard, A. Gossmann, A. Papyan Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth Int J Cancer 114 2005 131 138
18. A. Debucquoy, K. Haustermans, A. Daemen Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer J Clin Oncol 27 2009 2751 2757
19. H. Choi, C. Charnsangavej, S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 13 2007 1753 1759
20. K.M. Krajewski, M. Guo, A.D. Van den Abbeele Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma Eur Urol 59 2011 856 862
21. R. Thiam, L.S. Fournier, L. Trinquart Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib Ann Oncol 21 2010 936 941
22. H.Y. Lee, K.S. Lee, M.J. Ahn New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy Lung Cancer 73 2011 63 69
23. G.P. Schmidt, A. Baur-Melnyk, A. Haug Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer Eur Radiol 19 2009 1366 1378
24. B.A. Ward, D.L. Miller, J.A. Frank Prospective evaluation of hepatic imaging studies in the detection of colorectal metastases: correlation with surgical findings Surgery 105 1989 180 187
25. M.C. Niekel, S. Bipat, J. Stoker Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment Radiology 257 2010 674 684
26. J.P. O'Connor, C.J. Rose, A. Jackson DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6 Br J Cancer 105 2011 139 145
27. Y. Cui, X.P. Zhang, Y.S. Sun Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases Radiology 248 2008 894 900
28. D.M. Koh, E. Scurr, D. Collins Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients AJR Am J Roentgenol 188 2007 1001 1008
29. A.G. Sorensen Magnetic resonance as a cancer imaging biomarker J Clin Oncol 24 2006 3274 3281
30. R.G. Figueiras, V. Goh, A.R. Padhani The role of functional imaging in colorectal cancer AJR Am J Roentgenol 195 2010 54 66
31. C.D. Marcus, V. Ladam-Marcus, C. Cucu Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives Crit Rev Oncol Hematol 72 2009 217 238
32. H. Piessevaux, M. Schlichting, S. Heeger Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from crystal study Ann Oncol 21 Suppl 8 2010 (abstract 596P)
33. H. Piessevaux, C. Bokemeyer, M. Schlichting Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial J Clin Oncol 29 Suppl 4 2011 (abstract 398)
34. R.G. Amado, M. Wolf, M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
35. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
36. M. Giovannini, V. Gregorc, C. Belli Clinical significance of skin toxicity due to EGFR-targeted therapies J Oncol 2009 2009 849051
37. Z. Saridaki, M. Tzardi, C. Papadaki Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients PLoS ONE 6 2011 e15980
38. M. Peeters, S. Siena, E. Van Cutsem Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer 115 2009 1544 1554